This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Lt Col Lawrence H. Clouse, MC
USAF AFSC Regional Hospital Eglin Eglin Air Force Base, Fla

JAMA. 1989;261(7):987-988.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Buyse and colleagues¹ thoroughly reviewed the extensive literature on randomized, controlled trials of adjuvant chemotherapy for colorectal carcinoma. Coincidentally, this month the Southwest Oncology Group reported their fully mature adjuvant colorectal study,² seven years after the last patient accrual, and concluded that semustine and fluorouracil did not improve survival in treated patients compared with concurrent controls. It should be abundantly clear that adjuvant treatment for colorectal carcinoma with currently available drugs is a failure. It is not merely that we have yet to show a potential benefit; we have actually repeatedly and consistently failed to show a benefit sufficient to be meaningful to an individual patient. Indeed, few treatments in modern oncology have such a wealth of data documenting the futility of the approach.

It is true that some trials have shown a tiny benefit for the adjuvant approach; however, even when a trial accrues . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?